These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23511900)

  • 1. DRESS syndrome induced by acenocoumarol with tolerance to warfarin and dabigatran: a case report.
    Piñero-Saavedra M; Castaño MP; Camarero MO; Milla SL
    Blood Coagul Fibrinolysis; 2013 Jul; 24(5):576-8. PubMed ID: 23511900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    Schulman S; Kearon C; Kakkar AK; Schellong S; Eriksson H; Baanstra D; Kvamme AM; Friedman J; Mismetti P; Goldhaber SZ; ;
    N Engl J Med; 2013 Feb; 368(8):709-18. PubMed ID: 23425163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
    Hughes PJ; Freeman MK
    Consult Pharm; 2012 Jun; 27(6):445-52. PubMed ID: 22698551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
    Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A; Bailey C; Abdelhafiz AH
    Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of dabigatran immediately after atrial fibrillation ablation.
    Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):264-8. PubMed ID: 21955008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin versus dabigatran: comparing the old with the new.
    Abraham ME; Marcy TR
    Consult Pharm; 2012 Feb; 27(2):121-4. PubMed ID: 22330953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rash associated with dabigatran etexilate.
    To K; Reynolds C; Spinler SA
    Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl.
    Buyuktiryaki AB; Bezirganoglu H; Sahiner UM; Yavuz ST; Tuncer A; Kara A; Sackesen C
    Australas J Dermatol; 2012 Nov; 53(4):274-7. PubMed ID: 22524313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service.
    Atay JK; Fiumara K; Piazza G; Fanikos J; Goldhaber SZ
    Clin Appl Thromb Hemost; 2012; 18(2):181-4. PubMed ID: 21873358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of venous thromboembolism with dabigatran.
    Schulman S
    Curr Opin Pulm Med; 2012 Sep; 18(5):410-5. PubMed ID: 22617811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
    Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can dabigatran improve blood pressure control?
    Barrios V; Escobar C
    Future Cardiol; 2013 May; 9(3):321-3. PubMed ID: 23668738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
    Baruch L; Sherman O
    Ann Pharmacother; 2011 Jul; 45(7-8):e40. PubMed ID: 21712509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
    Blanco-Molina A
    Rev Clin Esp; 2012 Jan; 212 Suppl 1():3-7. PubMed ID: 23117646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.